Was the FDA misled by JUPITER?

J Am Osteopath Assoc. 2010 Aug;110(8):424-5.
No abstract available

MeSH terms

  • Biomarkers
  • C-Reactive Protein / drug effects
  • Cardiovascular Diseases / prevention & control*
  • Drug Approval*
  • Fluorobenzenes / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Primary Prevention / legislation & jurisprudence*
  • Pyrimidines / therapeutic use*
  • Risk Assessment
  • Rosuvastatin Calcium
  • Sulfonamides / therapeutic use*
  • United States
  • United States Food and Drug Administration*

Substances

  • Biomarkers
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium
  • C-Reactive Protein